The US Food and Drug Administration (FDA) has announced the recall of nearly 22,000 bottles of telmisartan and amlodipine manufactured by Viatris. The concern is that the tablets may contain more active ingredient than permitted. Although the recall is classified as Class III, indicating a low likelihood of adverse health consequences, patients should check the affected product and lot numbers.

(Staff: United States & India / Health & Consumer Affairs)

---

For millions of people around the world, taking a daily blood-pressure tablet is an established routine. The medication helps control hypertension, one of the most silent and dangerous health conditions. But even a treatment intended to protect patients can sometimes raise concerns. US authorities have issued a warning about a batch of medicine that may be stronger than specified.

A nationwide recall over potentially excessive strength

The FDA announced the recall of 21,620 bottles of blood-pressure medication containing 40 mg of telmisartan and 5 mg of amlodipine. Each bottle contains 30 tablets.

According to the FDA records, pharmaceutical company Viatris Inc. initiated the voluntary recall on 1 October. The official reason states that the telmisartan content in the affected lots may exceed the established specifications.

In other words, the tablets may contain more telmisartan than the specified amount. This does not mean the medicine is poison, but an unexpectedly high dose can cause unwanted effects.

How serious is the risk?

The FDA classified the action as a Class III recall, meaning that use of the product is unlikely to cause adverse health consequences. Nevertheless, patients should take the notice seriously and check the product details.

Too much telmisartan may lower blood pressure excessively and cause dizziness or a rapid heartbeat. In older people, dizziness can increase the risk of falls and related injuries.

How to check whether your medicine is affected

The affected bottles carry National Drug Code (NDC) 0378-1075-93. The affected lot numbers are:

• 3228113, 3228114 and 3228115 — expiration date: 31 October 2026.
• 3228120 and 3228121 — expiration date: 30 November 2026.

Check the label, usually near the expiry date, and contact your pharmacist or prescribing clinician if your bottle matches the listed code and lot number. Do not change or stop prescribed treatment without professional advice.

A wider manufacturing context

The recalled tablets were manufactured in India for Mylan Pharmaceuticals Inc., based in West Virginia. Mylan and Upjohn combined to form Viatris in 2020.

In March 2026, a Viatris subsidiary recalled a batch of Xanax XR 3 mg after tests found that it did not dissolve according to standards. In January, the company recalled a batch of methylprednisolone because packaging errors could have led to incorrect doses. These cases have raised questions about quality controls across the manufacturing chain.

Conclusion

Blood-pressure medicines are essential, and recalls such as this one show why pharmaceutical quality controls matter. Even a difference in the amount of an active ingredient can affect treatment safety.

Patients should check the product and lot number and ask a pharmacist or doctor for advice if anything is unclear. Do not stop a prescribed blood-pressure medicine on your own; a healthcare professional can explain the appropriate next step.